Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Merck Sharp & Dohme LLC0 个研究点开始时间: 2004年5月12日最近更新: 2019年11月14日

适应症

试验速览

To assess the effect of MK0493 on body weight, blood pressure, mood, and appetite.

•Patient is between 21 and 65 years
•Patient is able to read and understand and complete study questionnaires
•Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and post-study follow-up period

•Patient has a history of significant psychiatric disorder (such as major depression, bipolar disorder, bulimia, or anorexia nervosa
•Patient is HIV positive as determined by medical history
•Patient has undergone surgical treatment for obesity
•Patient plans to consume more than two 8 ounce glasses of grapefruit juice per day during the study
•Patient participated in another clinical study involving an investigational drug) within 3 months prior to Visit 1
•Patient is currently a heavy consumer of alcohol (>2 drinks per day or >14 drinks per week [1 drink is defined as 2 oz hard alcohol, 5 oz wine, 12 oz beer], or uses (including recreational use) any illicit drugs, or has a history of drug or alcohol abuse

发起方

申办方类型

Industry

责任方

Sponsor